Navigation Links
News briefs: May issue of the journal Chest
Date:5/4/2008

LATEST REVIEW SUGGESTS LABAs ARE SAFE AND EFFECTIVE FOR COPD

Previous research has linked the use of long-acting β2-agonists (LABA) to increased risk for adverse events or respiratory-related death in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD); however, a recent article shows this may not be the case. In a new metaanalysis, researchers from Spain, Argentina, and Uruguay reviewed the results of 27 randomized controlled clinical trials that met the following criteria: (1) study patients were over the age of 35 with stable COPD; (2) intervention included inhaled LABAs vs placebo, inhaled ipratropium bromide, or inhaled tiotropium; (3) studies were of at least 4 weeks duration; and (4) primary outcomes included severe exacerbations, all-cause mortality, and respiratory-related death. The review found that compared with placebo, LABAs reduced severe exacerbations by 21%, and patients given LABAs did not differ in all-cause or respiratory-related mortality. The review also found that LABA treatment was associated with significantly more severe COPD exacerbations compared with tiotropium. This study is published in the May issue of the journal CHEST.

ARDS MORTALITY RATES DECLINING

New research shows that, over the last decade, mortality rates for patients with acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) have steadily declined. In a metaanalysis, Belgian researchers reviewed 72 studies published between 1994 and 2006 that reported mortality rates for patients with ARDS or ALI. Mortality rates ranged from 15 to 72%, with the overall pooled mortality rate being 43%. Further analysis showed a significant decrease in overall mortality rates of approximately 1.1% per year over the decade analyzed. The decrease in mortality was more pronounced for hospital mortality than for mortality in the ICU. Researchers speculate that the decline in mortality may be the result of improvements in the treatment of patients with ARDS/ALI. This study is published in the May issue of the journal CHEST.

SMOKING PATTERN LINKED TO RARE PNEUMONIA

Acute eosinophilic pneumonia (AEP), a rare lung condition, may be associated with recent changes in smoking patterns. In a new study, Japanese researchers reviewed the smoking history and current smoking habits of 33 patients with AEP. All but one patient (97%) were current smokers. Alterations in smoking habits, such as initiating the smoking habit or increasing the number of cigarettes smoked, were seen in 87.9% of patients. Furthermore, a cigarette smoke provocation test was performed in nine patients, and all tested positive. Data suggest that cigarette smoking, particularly changes in smoking habits, is a possible AEP etiologic factor. This study is published in the May issue of the journal CHEST.


'/>"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
Source:Eurekalert

Related medicine news :

1. UPDATE: Retirement Living TV Partners With Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare 08: Search for Solutions
2. Lupus Organizations Issue International Call-to-Action to Combat Disease Affecting Five Million People
3. Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
4. American Lung Association Issues State of the Air Report: First City Outside California (Pittsburgh) Tops One of the Most-Polluted Lists
5. Retirement Living TV Partners with Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare 08: Search for Solutions
6. Patient Safety Authority Issues Annual Report for 2007
7. Three Million Californians Say Yes! to Organ and Tissue Donation
8. Congressional Organ and Tissue Donation Awareness Caucus Hosted Congressional Staff Meeting on April 29 to Spread the Truth About Organ Donation
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
11. Prominent Advocate on HIV/AIDS Issues Joins Altarum Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change Medicare health ... is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their ... D) need to make changes during this period order for their new policy to ...
(Date:12/2/2016)... ... ... More than half of American teens report losing their virginity before they ... child about sex related topics, less than 60 percent spoke about deeper themes like ... launch of its second edition of the “Sexual Wellness” campaign, aiming to address the ...
(Date:12/2/2016)... Milford, NJ (PRWEB) , ... December 02, 2016 , ... ... Nothing Water has some unique properties including its unmatched natural purity of just 6 ... as clean and crisp. , Nothing Water has been available in several ShopRite and ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... meals to needy individuals and families from eight different sites throughout Miami-Dade and ... Day. Over 1,000 volunteers worked very hard on Thanksgiving morning by putting together ...
(Date:11/30/2016)... ... 2016 , ... Northridge dentists, Dr. Assili and ... all patients. Understanding that budget can play a part in oral health maintenance, ... including discounts on many valuable dental treatments. Options for individuals, couples, and families ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)...  Eli Lilly and Company (NYSE: LLY ... provide updated financial guidance for 2016 on Thursday, December ... on that day with the investment community and media ... The conference call will begin at 10 a.m. ET. ... live webcast of the conference call through a link ...
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... -- Boston Scientific Corporation (NYSE: BSX ) ... assets and capabilities of the Neovasc, Inc., (NASDAQ: ... as well as a 15% equity stake in Neovasc, ... Neovasc advanced biological tissue business makes elements used in ... System. * Upon completion of the transaction, the ...
Breaking Medicine Technology: